OptiBiotix Health (LSE:OPTI) ROCE %

: -35.87% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OptiBiotix Health's annualized ROCE % for the quarter that ended in Jun. 2023 was -35.87%.

OptiBiotix Health ROCE % Historical Data

The historical data trend for OptiBiotix Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiBiotix Health Annual Data

Trend

Jul10

Jul12

Nov14

Nov15

Nov16

Nov17

Nov18

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

26.40

-26.07

55.62

38.04

15.84

OptiBiotix Health Semi-Annual Data
	Jul12	Jan13	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															140.46	-68.56	133.19	-136.94	-35.87

OptiBiotix Health ROCE % Calculation

OptiBiotix Health's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	2.441	/	( ( (20.145 - 0.602)	+	(11.548 - 0.278) )	/ 2 )
	=	2.441	/	( (19.543	+	11.27)	/ 2 )
	=	2.441	/	15.4065
	=	15.84 %

OptiBiotix Health's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-3.708	/	( ( (11.548 - 0.278)	+	(9.921 - 0.514) )	/ 2 )
	=	-3.708	/	( ( 11.27	+	9.407 )	/ 2 )
	=	-3.708	/	10.3385
	=	-35.87 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

OptiBiotix Health (LSE:OPTI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OptiBiotix Health ROCE % Related Terms

Thank you for viewing the detailed overview of OptiBiotix Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiBiotix Health (LSE:OPTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OptiBiotix Health PLC (LSE:OPTI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OPTI.GB:UK OB3:Germany

Address

Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG

Website

https://www.optibiotix.com

OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.